Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etrolizumab versus placebo in TNF inhibitor-experienced moderate to severe ulcerative colitis
NL-OMON47040Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Jan 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing Etrolizumab with Placebo (2 arms). Primary endpoints: Remission at Week 14 and Remission at Week 66 among Week 14 clinical responders. Started Jan 2015; status: active, not recruiting.
02
Drugs
Etrolizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON47040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47040.